Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The Role of Myosin VI as a Common Target of miR-143, miR-145, and miR-146 in del(5q) MDS/AML
EF 2009-10
Résumé
In healthy individuals, certain blood-forming cells known as stem cells are located within the bone marrow (BM). These cells differentiate and divide into essential blood cells (including red blood cells, white blood cells and platelets). However, those with a condition known as Myelodysplastic syndrome (MDS), have problems making these cells because their BM stem cells are damaged or defective. This leaves patients with abnormal blood cells and/or low blood counts, where approximately one-third of these patients develop a form of BM cancer known as acute myeloid leukemia (AML). Since both MDS and AML generally occur in older individuals, the number of MDS/AML cases is expected to increase dramatically as the population gets older. Unfortunately, since there is no cure for MDS, research to find better treatment options is vital. Within a cell, microRNAs (miRNA) are molecules which help regulate gene expression. There is accumulating evidence that suggests miRNA expression is an important factor in cancer. However, their roles in MDS are not well understood and more research is clearly needed. The focus of this project deals with a common subtype of MDS known as del(5q) where the BM cells have an unusual deletion on chromosome 5. Our lab has identified three miRNAs (miR-143, 145, 146) within this commonly deleted region which may mediate the symptoms of del(5q) MDS. Interestingly, all three miRNAs are predicted to share a single common target, namely MyosinVI (Myo6), which has previously been linked to immune signalling. Therefore, it is our hypothesis that these miRNA target Myo6, where their absence in del(5q) MDS patients result in the overexpression of Myo6 leading to inappropriate activation of immune signalling and ultimately, defective blood cells. If it is shown that these miRNAs are indeed responsible, and that Myo6 in particular plays a role, the data generated will have the potential to establish a novel treatment option for patients with MDS and leukemia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201558
Name
Lam Jeffrey C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The Role of Myosin VI as a Common Target of miR-143, miR-145, and miR-146 in del(5q) MDS/AML
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Flow Cytometry; Hematopoiesis; Innate Immunte Signaling; Micro Rna (Mirna); Mouse Bone Marrow Transplants; Myelodysplastic Syndrome; Myosin Vi (Myo6); Qrt-Pcr; Tgf-Beta Pathway
Abstract
In healthy individuals, certain blood-forming cells known as stem cells are located within the bone marrow (BM). These cells differentiate and divide into essential blood cells (including red blood cells, white blood cells and platelets). However, those with a condition known as Myelodysplastic syndrome (MDS), have problems making these cells because their BM stem cells are damaged or defective. This leaves patients with abnormal blood cells and/or low blood counts, where approximately one-third of these patients develop a form of BM cancer known as acute myeloid leukemia (AML). Since both MDS and AML generally occur in older individuals, the number of MDS/AML cases is expected to increase dramatically as the population gets older. Unfortunately, since there is no cure for MDS, research to find better treatment options is vital. Within a cell, microRNAs (miRNA) are molecules which help regulate gene expression. There is accumulating evidence that suggests miRNA expression is an important factor in cancer. However, their roles in MDS are not well understood and more research is clearly needed. The focus of this project deals with a common subtype of MDS known as del(5q) where the BM cells have an unusual deletion on chromosome 5. Our lab has identified three miRNAs (miR-143, 145, 146) within this commonly deleted region which may mediate the symptoms of del(5q) MDS. Interestingly, all three miRNAs are predicted to share a single common target, namely MyosinVI (Myo6), which has previously been linked to immune signalling. Therefore, it is our hypothesis that these miRNA target Myo6, where their absence in del(5q) MDS patients result in the overexpression of Myo6 leading to inappropriate activation of immune signalling and ultimately, defective blood cells. If it is shown that these miRNAs are indeed responsible, and that Myo6 in particular plays a role, the data generated will have the potential to establish a novel treatment option for patients with MDS and leukemia.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lam, Jeffrey C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~